Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
607 Results Found
HRSA Finalizes 340B Administrative Dispute Resolution Process
The Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) April 19 published the 340B Administrative Dispute Resolution (ADR) final rule establishing a process that was required under the Affordable Care Act.
AHA Statement on Final 340B Administrative Dispute Resolution Process Rule From HHS
The Administration’s final rule for the 340B drug pricing program administrative dispute resolution (ADR) process is an important step in ensuring the integrity of the 340B program. The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision.
HHS finalizes rule on 340B Administrative Dispute Resolution process
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the Affordable Care Act.
Senator Thune touts support for telehealth, urges solution-oriented advocacy
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year legislation that Congress will attempt to pass.
The Future of Health System-Based Cancer Care
Costly innovative cancer treatments and technologies, organizational alignments and shifting sites of care are changing the way care is delivered.
The 340B Drug Pricing Program
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs. Despite significant oversight from HRSA and the program’s proven record of decreasing government spending and expanding access to patient care, some want to scale it back or drastically reduce the benefits that eligible hospitals and their patients receive from the program.
AHA Responds to Senate RFI on the SUSTAIN 340B Act Draft
AHA welcomes the opportunity to provide feedback on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of (SUSTAIN) 340B Act bipartisan discussion draft and accompanying request for information on the critically important 340B Drug Pricing Program.
AHA comments on draft Senate bill to clarify, protect 340B program
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the 340B program and protect 340B providers from egregious behavior by drug companies, insurers and pharmacy benefit managers.
Amicus Brief: Academic Medical Centers Support AHA in 340B Case September 10, 2021
In 1990, Congress enacted the Medicaid Rebate Program, as part of the Omnibus Reconciliation Act of 1990 (Pub. L. No. 101-508).20. This law requires drug companies that choose to participate in Medicaid to give states, which administer Medicaid, discounts comparable to those given to other payers.